Negative impactEconomy
AI cannot replace clinical trials soon, warns Moderna co-founder Noubar Afeyan
BusinessLine 1 hr ago·14 Oct 2026, 7:33 am
Moderna co-founder Noubar Afeyan has cautioned investors against overhyping Artificial Intelligence in drug development. He argues that AI cannot replace traditional clinical trials soon, as researchers still lack a complete understanding of human physiology. This perspective suggests that the current excitement around AI in biotech may be premature.
For investors, this highlights the importance of focusing on the practical, long-term progress of drug pipelines rather than speculative trends. It serves as a reminder that scientific breakthroughs require time and rigorous testing. Investors should remain cautious about valuations in the biotech sector that might be driven by hype rather than proven results.
Moving forward, market participants should watch for updates on actual clinical trial data. The sector’s performance will likely depend on tangible scientific milestones rather than the potential of AI alone. Investors are advised to maintain a balanced view of the sector's growth prospects.
Excerpt from BusinessLine
Artificial intelligence (AI) could transform scientific discovery and accelerate drug development, but replacing clinical trials with digital simulations remains a distant prospect given the complexity of human biology, Noubar Afeyan, co-founder and chairman of Moderna, said at the Bloomberg New Economy Forum in New…Read the original at BusinessLine
Key takeaways
- Category: Economy.
- AI reads the tone as negative (potentially bearish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
